Group 1 - Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule product candidates for serious diseases, including oncology and obesity [3] - The company has granted an equity inducement award to a new employee as part of its 2022 Employment Inducement Award Plan, which was approved by the Compensation Committee [1][2] - The equity award consists of options to purchase 20,000 shares of common stock at an exercise price of $8.10, with a vesting period of four years [2] Group 2 - Terns' pipeline includes three clinical stage development programs: an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, and a THR-β agonist, along with a preclinical GIPR modulator discovery effort [3]

Core Viewpoint - The Chinese stock market is experiencing renewed optimism as major financial institutions upgrade their ratings on Chinese stocks, driven by government policy actions and potential earnings growth [1][2]. Group 1: Market Outlook - Goldman Sachs has raised its rating on Chinese stocks to "overweight," anticipating an increase in benchmark valuations due to decisive policy actions by the Chinese government [1]. - Citigroup has also upgraded its ratings on Chinese consumer and real estate stocks, reflecting a positive sentiment in these sectors [1]. - Analysts from Goldman Sachs predict a potential upside of 15% to 20% for Chinese stocks, supported by recent strong rebounds and valuations below the median range [1]. Group 2: Index Targets - Goldman Sachs has increased its 12-month target for the MSCI China Index to 84 points and the CSI 300 Index to 4600 points, indicating a total return rate of 15% to 18% [1]. Group 3: Sector Preferences - Citigroup analysts favor internet stocks, maintaining an "overweight" stance due to strong fundamentals and positive effects from consumption stimulus measures [2].

Core Points - Cidara Therapeutics, Inc. announced the grant of stock options and restricted stock units (RSUs) to a new employee, Dipesh Bhatt, totaling 1,110 shares under the 2020 Inducement Incentive Plan, with an exercise price of $10.75 per share [1][2] - The stock options will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting in 36 equal monthly installments, while the RSUs will vest in four equal annual installments [1] - The equity award was granted as an inducement for the employee's entry into employment with Cidara, in compliance with Nasdaq Listing Rule 5635(c)(4) [2] Company Overview - Cidara Therapeutics utilizes its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies aimed at improving patient care for serious diseases [1][4] - The lead DFC candidate, CD388, is designed for universal prevention of seasonal and pandemic influenza with a single dose and has received Fast Track Designation from the FDA [4] - Cidara is also developing additional DFCs for oncology, including CBO421, which targets CD73 in solid tumors and received IND clearance in July 2024 [4]

The Federal Reserve has terminated a decade-long enforcement action against Citigroup Inc. (C) , which was filed over weaknesses in the bank's anti-money laundering (AML) practices.Background of Citigroup’s Enforcement ActionIn March 2023, the Federal Deposit Insurance Corporation and the Office of the Comptroller of the Currency raised concerns over insufficient controls and risk management practices pertaining to the Bank Secrecy Act (BSA) and AML requirements.The enforcement action didn’t include any fin ...

The Federal Reserve has terminated a decade-old enforcement action against Citigroup that focused on deficiencies tied to the banking giant’s anti-money laundering (AML) practices.On Oct. 1, the central bank announced the termination of the 2013 action — one that had not carried a fine. But the action does discuss several changes to various bank-wide efforts to monitor and address risk, and to report its findings periodically to regulators.In terms of the consent order itself, the Fed had brought its action ...

Citigroup Inc. (C) and Apollo Global Management Inc. (APO) have inked a deal for a subsidiary of Citigroup and certain affiliates of Apollo to establish a revolutionary $25-billion private credit, direct lending program. The program will initially focus on North America, potentially expanding to additional geographies. Both companies expect the program to finance approximately $25 billion of debt opportunities over the next several years, including corporate and financial sponsor transactions.  Citigroup an ...

Citigroup Inc. (C) is in the limelight with the Federal Reserve’s aggressive start to monetary policy easing. During the Sept. 17-18 FOMC meeting, the Fed lowered the interest rate by 50 basis points after more than four years. Currently, the Fed fund rates stand in the 4.75-5% range. The central bank also indicated two more rate cuts this year and four in 2025. This is expected to bring rates down to 3.4% by the end of next year.The rate cut is a positive development for banks like Citigroup, Wells Fargo ( ...

The most recent trading session ended with Citigroup (C) standing at $62.58, reflecting a +0.71% shift from the previouse trading day's closing. The stock exceeded the S&P 500, which registered a gain of 0.28% for the day. Meanwhile, the Dow experienced a rise of 0.15%, and the technology-dominated Nasdaq saw an increase of 0.15%.Heading into today, shares of the U.S. bank had 0% over the past month, lagging the Finance sector's gain of 3.08% and the S&P 500's gain of 2% in that time.Investors will be eager ...

Citigroup Inc.’s (C) plan to expand in China has met a snag with the U.S. regulators after the Federal Reserve imposed a penalty on the bank related to its data management and risk controls, per a Bloomberg report.The bank is currently awaiting a clearance letter from the U.S. Federal Reserve, which is required by Chinese authorities to verify Citigroup's regulatory standing. Without this letter, the bank cannot proceed with its plans to set up a standalone securities firm in China.The difficulties arose wh ...

Citi's plan to expand in China has reportedly hit a regulatory bump in America. The trouble stems from a penalty levied by the Federal Reserve against the banking giant over its data management and risk controls, Bloomberg News reported Monday (Sept. 23), citing sources familiar with the matter. According to the report, Citi faces delays in establishing a standalone securities office because it hasn't yet gotten a clearance letter from the Fed verifying its regulatory standing, something required by the gov ...